Mandate

Vinge has advised ABG Sundal Collier and Carnegie in connection with Permascand’s listing on Nasdaq First North Premier Growth Market

June 04, 2021

Vinge has advised ABG Sundal Collier and Carnegie in connection with Permascand’s listing on Nasdaq First North Premier Growth Market. Trading on Nasdaq First North Premier Growth Market commenced on 4 June 2021.

The price per share in the offering was SEK 34 per share, corresponding to a total value of approximately SEK 2,017 million for all outstanding shares in the Permascand following the completion of the offering. The Offering comprised 14,860,627 shares, corresponding to approximately 25.1 percent of the total number of shares in the company following the completion of the offering, of which 8,823,529 shares were newly issued shares and 6,037,098 shares were existing shares sold by Norvestor VI, L.P. and a few other shareholders

Permascand is an independent technology-driven manufacturer of electrochemical solutions based on proprietary catalytic coatings for cleantech applications. With a customer-centric focus, Permascand has supplied electrodes, electrochemical cells, and aftermarket services to a variety of sectors for the past 50 years.

Vinge’s team consisted of Dain Hård Nevonen, Linnéa Sellström and Eléonore Friberg.

Related

Vinge advises Sobro on its investment in Västkustens Konstruktionsbyrå

Västkustens Konstruktionsbyrå has decided to broaden its ownership structure by bringing in Sobro as a new co-partner and majority shareholder. The founders will remain with the company as the CEO and CTO respectively, and as significant shareholders. Västkustens Konstruktionsbyrå is an engineering consultancy company based in Gothenburg with cutting-edge expertise in project management, civil engineering and design.
April 23, 2026

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026